How many clinical trials are tracked for Geographic Atrophy?

20 trials are tracked, 5 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Geographic Atrophy

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Geographic Atrophy

20 trials tracked for Geographic Atrophy: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 438 citations.

20Trials tracked

6Phase 3 & 4

0Recruiting

5With published results

Phase distribution

Phase 3 6 Phase 2 10 Other / NA 4

Phase 3 Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Completed · 438 cited
Phase 3 A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Completed · 434 cited
Phase 3 Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Completed · 432 cited
Phase 3 A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) Completed · 311 cited
Phase 3 Phase 2/3 Study of ALK-001 in Geographic Atrophy Completed · 46 cited
Phase 3 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Completed

Show 14 more trials

Phase 2 Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) Completed
Phase 2 Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD Completed
Phase 2 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Completed
Phase 2 Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration Completed
Phase 2 CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) Completed
Phase 2 Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Completed
Phase 2 Sirolimus for Advanced Age-Related Macular Degeneration Completed
Phase 2 A Study of NGM621 in Participants With Geographic Atrophy Completed
Phase 2 A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy Completed
Phase 2 A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy Completed
N/A Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD Completed
N/A Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Completed
N/A Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE) Completed
N/A Patients With Geographic Atrophy and Their Patient Journey in the United States (US) Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.